ARTICLE | Finance
Early opportunity
How Forty Seven plans to spend its $75M series B
October 20, 2017 8:16 PM UTC
Preliminary data from ongoing studies of lead candidate Hu5F9-G4 enabled Forty Seven Inc. to raise a $75 million series B round sooner than expected.
The new funds will allow Forty Seven to launch and complete three additional studies of Hu5F9-G4 in combination with undisclosed checkpoint inhibitors, and thus evaluate a broader range of combination regimens before deciding on a registrational trial strategy...
BCIQ Company Profiles
BCIQ Target Profiles